• Je něco špatně v tomto záznamu ?

Unravelling heterogeneous effects of cancer‐associated fibroblasts on poor prognosis markers in breast cancer EM‐G3 cell line: In vitro‐targeted treatment (anti‐IL-6, anti‐VEGF-A, anti‐MFGE8) based on transcriptomic profiling

L. Urban, Š. Novák, M. Čoma, B. Dvořánková, L. Lacina, J. Šáchová, M. Hradilová, P. Svatoňová, M. Kolář, H. Strnad, J. Březinová, K. Smetana, P. Gál, P. Szabo

. 2024 ; 51 (1) : . [pub] 20231117

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000108

Breast cancer is the most frequently diagnosed cancer in women worldwide. Although dramatically increased survival rates of early diagnosed cases have been observed, late diagnosed patients and metastatic cancer may still be considered fatal. The present study's main focus was on cancer‐associated fibroblasts (CAFs) which is an active component of the tumor microenvironment (TME) regulating the breast cancer ecosystem. Transcriptomic profiling and analysis of CAFs isolated from breast cancer skin metastasis, cutaneous basal cell carcinoma, and squamous cell carcinoma unravelled major gene candidates such as IL6, VEGFA and MFGE8 that induced co‐expression of keratins‐8/‐14 in the EM‐G3 cell line derived from infiltrating ductal breast carcinoma. Western blot analysis of selected keratins (keratin‐8, ‐14, ‐18, ‐19) and epithelial‐mesenchymal transition‐associated markers (SLUG, SNAIL, ZEB1, E‐/N‐cadherin, vimentin) revealed specific responses pointing to certain heterogeneity of the studied CAF populations. Experimental in vitro treatment using neutralizing antibodies against IL-6, VEGF‐A and MFGE8 attenuated the modulatory effect of CAFs on EM‐G3 cells. The present study provided novel data in characterizing and understanding the interactions between CAFs and EM‐G3 cells in vitro. CAFs of different origins support the pro‐inflammatory microenvironment and influence the biology of breast cancer cells. This observation potentially holds significant interest for the development of novel, clinically relevant approaches targeting the TME in breast cancer. Furthermore, its implications extend beyond breast cancer and have the potential to impact a wide range of other cancer types.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000108
003      
CZ-PrNML
005      
20240716101615.0
007      
ta
008      
240109s2024 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/or.2023.8662 $2 doi
035    __
$a (PubMed)37975220
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Urban, Lukáš $u Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, 040 11 Košice, Slovak Republic
245    10
$a Unravelling heterogeneous effects of cancer‐associated fibroblasts on poor prognosis markers in breast cancer EM‐G3 cell line: In vitro‐targeted treatment (anti‐IL-6, anti‐VEGF-A, anti‐MFGE8) based on transcriptomic profiling / $c L. Urban, Š. Novák, M. Čoma, B. Dvořánková, L. Lacina, J. Šáchová, M. Hradilová, P. Svatoňová, M. Kolář, H. Strnad, J. Březinová, K. Smetana, P. Gál, P. Szabo
520    9_
$a Breast cancer is the most frequently diagnosed cancer in women worldwide. Although dramatically increased survival rates of early diagnosed cases have been observed, late diagnosed patients and metastatic cancer may still be considered fatal. The present study's main focus was on cancer‐associated fibroblasts (CAFs) which is an active component of the tumor microenvironment (TME) regulating the breast cancer ecosystem. Transcriptomic profiling and analysis of CAFs isolated from breast cancer skin metastasis, cutaneous basal cell carcinoma, and squamous cell carcinoma unravelled major gene candidates such as IL6, VEGFA and MFGE8 that induced co‐expression of keratins‐8/‐14 in the EM‐G3 cell line derived from infiltrating ductal breast carcinoma. Western blot analysis of selected keratins (keratin‐8, ‐14, ‐18, ‐19) and epithelial‐mesenchymal transition‐associated markers (SLUG, SNAIL, ZEB1, E‐/N‐cadherin, vimentin) revealed specific responses pointing to certain heterogeneity of the studied CAF populations. Experimental in vitro treatment using neutralizing antibodies against IL-6, VEGF‐A and MFGE8 attenuated the modulatory effect of CAFs on EM‐G3 cells. The present study provided novel data in characterizing and understanding the interactions between CAFs and EM‐G3 cells in vitro. CAFs of different origins support the pro‐inflammatory microenvironment and influence the biology of breast cancer cells. This observation potentially holds significant interest for the development of novel, clinically relevant approaches targeting the TME in breast cancer. Furthermore, its implications extend beyond breast cancer and have the potential to impact a wide range of other cancer types.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a antigeny povrchové $7 D000954
650    12
$a nádory prsu $x farmakoterapie $x genetika $x metabolismus $7 D001943
650    12
$a fibroblasty asociované s nádorem $x metabolismus $7 D000072645
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a fibroblasty $x metabolismus $7 D005347
650    _2
$a keratiny $x genetika $x metabolismus $7 D007633
650    _2
$a MFC-7 buňky $7 D061986
650    _2
$a mléčné bílkoviny $x genetika $x metabolismus $7 D008894
650    _2
$a prognóza $7 D011379
650    _2
$a transkriptom $7 D059467
650    _2
$a nádorové mikroprostředí $x genetika $7 D059016
650    _7
$a maligní melanom kůže $7 D000096142 $2 czmesh
655    _2
$a časopisecké články $7 D016428
700    1_
$a Novák, Štepán $u Institute of Anatomy, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic
700    1_
$a Čoma, Matúš $u Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, 040 11 Košice, Slovak Republic
700    1_
$a Dvořánková, Barbora $u Institute of Anatomy, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic
700    1_
$a Lacina, Lukáš $u Institute of Anatomy, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic
700    1_
$a Šáchová, Jana $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics, Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Hradilová, Miluše $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics, Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Svatoňová, Petra $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics, Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Kolář, Michal $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics, Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Strnad, Hynek $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics, Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Březinová, Jana $u Cytogenetic Laboratory, Institute of Hematology and Blood Transfusion, 128 00 Prague, Czech Republic
700    1_
$a Smetana, Karel $u Institute of Anatomy, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic
700    1_
$a Gál, Peter, $u Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, 040 11 Košice, Slovak Republic $d 1981- $7 xx0320027
700    1_
$a Szabo, Pavol $u Institute of Anatomy, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic
773    0_
$w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 51, č. 1 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37975220 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240716101611 $b ABA008
999    __
$a ok $b bmc $g 2049040 $s 1209802
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 51 $c 1 $e 20231117 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace